BioStock: Saniona made further progress during Q3

Saniona’s Q3 report underscores a period of heightened activity, extending beyond the quarter’s confines. A notable development is the collaboration with AstronauTx in Alzheimer’s research, potentially yielding milestone payments of up to 177 MUSD for Saniona. The company is also making strides in its Kv7 epilepsy treatment program. Collectively, this marks a positive shift following the challenges that the company encountered in 2022.

Read the article at biostock.se:

https://www.biostock.se/en/2023/12/saniona-made-further-progress-during-q3/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/